No profile yet.
According to SCMP Business, InnoCare Pharma, a Beijing-based cancer drug developer, said it had entered into a strategic research collaboration and licensing agreement with Eli Lilly that could be worth up to US$3.35 billion.
According to CNBC Technology, Novo Nordisk shares have dropped more than 10% this week, on track for their worst performance since February, while Eli Lilly shares have climbed about 2.5%. The report notes Novo’s plan to diversify beyond its weight loss drugs with a broader pipeline, and mentions Lilly’s uptake of its GLP-1 therapy Foundayo.
Viking Therapeutics released obesity drug data causing its stock to skyrocket.
According to IT Home, Novo Nordisk is exploring the hair loss treatment market to diversify its consumer prescription drug business, leveraging its expertise in endocrinology. Chief Scientific Officer Martin Lange stated that while hair loss is not currently in the top priority list for mid-stage trials, the company aims to launch some consumer-focused products by 2030.
None yet.
Viking Therapeutics released obesity drug data causing its stock to skyrocket.
